Long-term Effect of Lanthanum Carbonate on Bone

• Status: Completed
• Trial end date: 2010-08-31
• Target enrollment: 0
• Participant gender: All

Summary

Patients enrolled in a previous study (SPD405-309), who were exposed to lanthanum carbonate (Fosrenol), were eligible to continue on any prescribed treatment for hyperphosphatemia, including lanthanum carbonate (Fosrenol), for an additional 5 years. Patients were being observed for any bone adverse events or other serious adverse events, as well as the collection of mortality data.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shire

Criteria

Inclusion Criteria:

• Any patient who had exposure to lanthanum carbonate in SPD405-309